



MEDICATION PRIOR AUTHORIZATION REQUEST FORM

FAX this completed form to 1-888-865-6531
OR Mail request to: Pharmacy Services Prior Authorization Dept.
5 River Park Place East, Suite 210 | Fresno, CA 93720

Call 1-833-705-1351 to request a 72-hour supply of medication.
Pharmacy Services will respond via fax or phone within 24 hours of receipt of all necessary information,
expect during weekends and holidays. For immediate response on weekends and holidays, NurseWise will answer your call.

VFEND (Voriconazole)

(Maximum of 90 Days Approval) Note: Form must be completed in full. An incomplete form may be returned

Recipient's Medicaid ID#

Date of Birth (MM/DD/YYYY)

Recipient's Full Name

Prescriber's Full Name

Prescriber's NPI

Prescriber Phone Number

Prescriber Fax Number

Vfend (voriconazole)
Initiation of therapy
Continuation of therapy

50 mg tab
200 mg tab

40 mg/ml susp.
200 mg vials (IV)

Directions, Quantity/30 Days, Weight (lbs, kgs)

1. Please check all that apply: (Vfend not FDA approved for prophylactic therapy).

- Invasive Aspergillosis (Only approved indication for primary treatment)
Candidemia in non-neutropenic patients
Candidiasis of the esophagus
Disseminated candidiasis of the skin and infections in the abdomen, kidney, bladder wall, and wounds
Serious infections due to Scedosporium apiospermum and Fusarium spp., including Fusarium solani

2. Has patient received transplant? Yes No

Type: Date:

3. What antifungal agent(s) has the patient received in the past 90 days?

Drug Name: Dates of Use:

Reason for Discontinuing:

Drug Name: Dates of Use:

Reason for Discontinuing:

4. Site(s) of Infection:

5. Diagnostic test(s) performed include: (check all that apply and submit copy of test results)

- Platelia Aspergillus EIA test
Thoracic CT
Culture(s)
Biopsy

6. Vfend prescribed by: Hematologist Oncologist, or Infectious Disease Specialist

Prescriber's Signature: Date:

REQUIRED FOR REVIEW: All copies of medical records (e.g., diagnostic evaluations and recent chart notes), and the most recent copies of related labs. The provider must retain copies of all documentation for five years.

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited.



**MEDICATION PRIOR AUTHORIZATION REQUEST FORM**

**FAX this completed form to 1-888-865-6531**

**OR Mail request to: Pharmacy Services Prior Authorization Dept.  
5 River Park Place East, Suite 210 | Fresno, CA 93720**

Call 1-833-705-1351 to request a 72-hour supply of medication.

Pharmacy Services will respond via fax or phone within 24 hours of receipt of all necessary information, expect during weekends and holidays. For immediate response on weekends and holidays, NurseWise will answer your call.

**VFEND<sup>®</sup> (Voriconazole)**

**(Maximum of 90 Days Approval) Note: Form must be completed in full. An incomplete form may be returned**

**Approved Indications:**

**Invasive Aspergillosis:**

- a. The “Invasive Aspergillosis” diagnosis must be checked.
- b. **Initial treatment** will be approved for **1 month** in patients suspected of having a life-threatening invasive Aspergillus infection that meet the following criteria:
  - Have a diagnosis indicating they are immunocompromised or are currently receiving immunosuppressive drugs; **AND**
  - Patient has clinical manifestations (symptoms, signs, and radiological features) compatible with the diagnosis of invasive aspergillosis. (**Supporting documentation must accompany request.**)
- c. The **remaining 60 days of therapy** may be granted upon receipt of a positive **Platelia Aspergillus EIA test** (detects circulating galactomannan antigen), biopsy or culture. A copy of the original lab results is required.
- d. New test results must accompany request for continuation of therapy after initial 90 days of therapy.

**Treatment Failures:**

Patient must have documented treatment failure with one or more of the following (except in the case of invasive aspergillosis):

- Amphotericin B (Abelcet<sup>®</sup>, Fungizone<sup>®</sup>)
- Flucanazole (Diflucan<sup>®</sup>)
- Ketoconazole (Nizoral<sup>®</sup>)

Indication	PDL Alternatives (Current December 2007)
Invasive Aspergillosis	Abelcet, amphotericin B, Fungizone
Candidemia in non-neutropenic patients	Abelcet, amphotericin B, fluconazole, Fungizone
Candidiasis of the Esophagus	Abelcet, amphotericin B, fluconazole, Fungizone, ketoconazole
Disseminated candidiasis of the skin, and infections in the bladder wall, abdomen, kidney, and wounds	Abelcet, amphotericin B, fluconazole, Fungizone
<i>Scedosporium apiospermum</i> and <i>Fusarium</i> species including <i>Fusarium solani</i>	Abelcet, amphotericin B, Fungizone